Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse
about
Proteoglycan form and function: A comprehensive nomenclature of proteoglycansRecent Insights into Cell Surface Heparan Sulphate Proteoglycans and CancerSyndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and PrognosticationMechanisms of heparanase inhibitors in cancer therapy.Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancerShed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk.Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies.Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma CellsSoluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumorsSyndecans as modulators and potential pharmacological targets in cancer progression.What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.Immunoglobulin Free Light Chains and GAGs Mediate Multiple Myeloma Extracellular Vesicles Uptake and Secondary NfκB Nuclear Translocation.A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
P2860
Q21710680-C5980235-A901-447D-B05E-8A077B665F4AQ26740617-8916BC83-08C4-4FAB-AC0B-76BF4FBB98F2Q26784262-CD17FFD7-5101-400F-9EE1-3F03789BFC9BQ30244089-A9EF3CCF-2A2A-47CE-98B3-D4DF95B8503BQ34039967-E6E28E82-8789-4263-ACA9-81EA0C9A1F3BQ34499650-3A01CB74-783C-4BF7-9945-08BE14B94C2FQ34958906-99B0C685-FC7E-4732-AD27-20EE1ED309F5Q35830856-73F68519-0F18-43CE-BEC1-4E18749F504DQ36208283-FA642B09-FCB6-49A3-A1F9-AEF0B0A9EF95Q37641801-370F5446-3632-45A4-9857-4B119367CF21Q38176008-0C26E988-3E3A-4BB0-8D75-5568F1821628Q38189392-73BCAFC8-3FB0-4122-80F4-E3060DD00333Q38256196-14953FB0-F926-4EAF-85D0-6FD6C140E5AEQ41158870-E29945F9-0C86-4F04-AD2E-A9D507D2E5DBQ42962110-8D4BF222-8400-4B52-957F-DE6C54849F32Q48026733-B4762742-D4B1-4EE7-A498-A14F9C1DB26F
P2860
Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Chemotherapy stimulates syndec ...... that may promote tumor relapse
@en
Chemotherapy stimulates syndec ...... that may promote tumor relapse
@nl
type
label
Chemotherapy stimulates syndec ...... that may promote tumor relapse
@en
Chemotherapy stimulates syndec ...... that may promote tumor relapse
@nl
prefLabel
Chemotherapy stimulates syndec ...... that may promote tumor relapse
@en
Chemotherapy stimulates syndec ...... that may promote tumor relapse
@nl
P2860
P1433
P1476
Chemotherapy stimulates syndec ...... that may promote tumor relapse
@en
P2093
Ralph D Sanderson
Vishnu C Ramani
P2860
P304
P356
10.1016/J.MATBIO.2013.10.005
P577
2013-10-18T00:00:00Z